Comorbidity evaluation tool shows usefulness for elderly nasopharyngeal carcinoma patients

  • Wen YF & al.
  • J Cancer
  • 1 Jan 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The Adult Comorbidity Evaluation-27 (ACE-27) score is associated with cancer-specific survival (CSS) in patients aged ≥70 years with locoregionally advanced nasopharyngeal carcinoma (NPC).

Why this matters

  • Better prognostic tools can help guide patient management.

Key results

  • ACE-27 score ≥2 was associated with reduced CSS in multivariate analysis (HR, 2.359; P<.001 style="list-style-type:circle;">
  • ACE-27 score was also associated with OS (HR, 2.350; P<.001 pfs p and locoregional relapse-free survival>
  • Addition of chemotherapy to intensity-modulated radiotherapy (IMRT) was not associated with changes in 3-year CSS rates compared with IMRT alone in multivariate analysis (HR, 1.221; P=.419) or propensity score-matched analysis (64.3% vs 65.2%; P=.764).
  • In subgroup analysis, the addition of chemotherapy to IMRT was associated with a lower 3-year CSS rate compared with IMRT alone in patients with an ACE-27 score ≥2 (46.3% vs 63.5%; P=.041).
  • Study design

    • 206 patients aged ≥70 years with locoregionally advanced NPC who received IMRT with or without chemotherapy were analyzed for CSS and associations with ACE-27 score.
    • Funding: National Key R&D Program of China; National Natural Science Foundation of China; Sun Yat-Sen University, Guangzhou City; National Key Basic Research Program of China, Guangdong Province; others.

    Limitations

    • Retrospective study with short follow-up.